vipoglanstat
AssetAlso called GS-248
Inhibits microsomal prostaglandin E synthase-1, reducing production of pro-inflammatory prostaglandin E2.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- PTGES
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Endometriosis
Phase 2, Active not recruiting, NCT07260669, clinicaltrials.gov, Oct 21, 2026
In the full profile
- Target and mechanism1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors4
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.